Nuvo Research Announces Scientific Presentation at the Annual Meeting of the American Association of Immunologists
May 16, 2013
Data Evaluating WF10's Therapeutic Impact on Signs and Symptoms of Experimentally Induced Rheumatoid Arthritis in Mice
MISSISSAUGA, ON, May 16, 2013 /CNW/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10 today announced that researchers from the Fraunhofer Institute for Cell Therapy and Immunology IZI and Nuvo presented scientific data related to WF10's therapeutic impact on signs and symptoms of experimentally induced rheumatoid arthritis in mice at the 100th Annual Meeting of The American Association of Immunologists (AAI) in Honolulu, Hawaii, U.S.
Compared to the placebo group, animals treated with WF10 showed a reduction of the degree of symptoms. Based on these results, the investigators concluded that WF10 may present a novel therapeutic approach for patients suffering from rheumatoid arthritis and other inflammatory autoimmune diseases. Rheumatoid arthritis is a complex chronic autoimmune disease and the most common inflammatory disorder of joints leading to cartilage destruction, bone erosion and deformation of joints. The initializing causes of rheumatoid arthritis are not fully understood and thus there can be no guarantee that the results observed in this animal model will be reproducible in humans.
"This joint poster presentation is a result of the deep and fruitful cooperation between Nuvo and the prestigious Fraunhofer Institute in Leipzig, Germany," said Dr. Henrich Guntermann, Nuvo's President, Europe and Immunology Group. "With our partners in Leipzig and supported by funding from the Development Bank of Saxony (SAB) and the European Fund for Regional Development (EFRE), we are currently working on multiple research and development projects to further explore WF10's full potential."
The immune system provides an essential defense to microorganisms, cancer and substances it sees as foreign and potentially harmful. WF10 focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function. In conditions such as allergic rhinitis, the body's immune system inappropriately responds to the presence of foreign allergens. Research suggests that in some cases, WF10 may rebalance improperly functioning immune systems. WF10 is an infusion therapy currently approved only in Thailand under the name IMMUNOKINE for treatment of postradiation chronic inflammatory disease and diabetic foot ulcer. WF10 is not yet approved for the treatment of rheumatoid arthritis and was used in the reported study on an investigational basis.
About Fraunhofer Institute for Cell Therapy and Immunology IZI
The Fraunhofer Institute for Cell Therapy and Immunology IZI is a member of the Fraunhofer Group for Life Sciences. Its objective is to find solutions for specific problems at the interfaces of medicine, life sciences and engineering. It supports partners active in medicine-related industries and businesses.
About Nuvo Research Inc.
Nuvo is a publicly traded, Canadian specialty pharmaceutical company, headquartered in Mississauga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal research and development. The Company's product portfolio includes Pennsaid®, Pliaglis® and Synera®. Pennsaid, a topical nonsteroidal anti-inflammatory drug (NSAID), is used to treat the signs and symptoms of osteoarthritis of the knee(s). Pennsaid is sold in the United States by Mallinckrodt Inc., a Covidien company, in Canada by Paladin Labs Inc. and in several European countries. Pliaglis is a topical local anesthetic cream which provides topical local analgesia for superficial dermatological procedures. The Company has licensed worldwide marketing rights to Pliaglis to Galderma Pharma S.A., a global pharmaceutical company specialized in dermatology. Synera is a topical patch that combines lidocaine, tetracaine and heat, approved in the United States to provide local dermal analgesia for superficial venous access and superficial dermatological procedures and in Europe, for surface anaesthesia of normal intact skin. Nuvo currently markets Synera in the United States and its licensing partner, Eurocept International B.V., has initiated a pan-European launch of Synera (under the name Rapydan®) in several European countries. The Company is also developing WF10, for the treatment of immune related diseases.
Certain statements in this news release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements concerning the Company's future objectives, strategies to achieve those objectives, as well as statements with respect to management's beliefs, plans, estimates, and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "outlook", "objective", "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "should", "plans" or "continue", or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include the need for additional financing, the current economic environment, dependence on sales and marketing partnerships, competitive developments, as well as other risk factors included in the Company's annual information form dated March 27, 2013 under the heading "Risks Factors" and as described from time to time in the reports and disclosure documents filed by the Company with Canadian securities regulatory agencies and commissions. This list is not exhaustive of the factors that may impact the Company's forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Company's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and neither the Company nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. The factors underlying current expectations are dynamic and subject to change. Although the forward-looking information contained in this news release is based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. Certain statements included in this news release may be considered "financial outlook" for purposes of applicable securities laws, and such financial outlook may not be appropriate for purposes other than this news release. All forward-looking statements in this news release are qualified by these cautionary statements. The forward-looking statements contained herein are made as of the date of this news release and except as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE: Nuvo Research Inc.
For further information:
Further information on Nuvo is available on the Company's website www.nuvoresearch.com or by contacting:
Email: [email protected]